CSI Market
Sign In | Register

Cadrenal Therapeutics Inc (CVKD) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CVKD Annual Cash Flow →
From Cadrenal Therapeutics Inc through Dec 31 2024, changes in Jun 30 2026's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Dec 31 2024)
Operating Activities
Income-5.82
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.92
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Operating Lease Right Of Use Asset Amortization Expense-
Issuance Of Shares To Settle Asset Purchase Agreement-
Income taxes0.00
Gain (Loss) on Sale of Derivatives0.00
Increase (Decrease) in Accrued Interest Receivable, Net0.00
Increase (Decrease) in Accounts Payable0.22
Increase (Decrease) in Accrued Liabilities-0.36
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.20
Other Working Capital0.01
Other Noncash Income (Expense)0.90
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.31
Discontinued operations0.00
Net Cash flow from Operating Activities-5.24
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.08
Long-term debt - borrowings0.08
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.46
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock2.57
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-0.56
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents10.02
Stock Issued-
Proceeds From Sale Of Common Stock Prefunded Warrants And Warrants In Private Placement Net-
Proceeds From Issuance Costs Warrant Inducement-
Proceeds From Issuance Costs Warrant Induceme-
Proceeds From The Sale Of Common Stock And Warrants-
Issuance Costs For The Sale Of Common Stock And Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities3.61
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-5.23
Total Cash Flow-1.62
4 historic quarters locked

Sign in to unlock the full Cadrenal Therapeutics Inc cash flow history.

Sign In Create Free Account

About Cadrenal Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-26-089153

Figures are derived from filed reports and may be restated. Historical data is subject to revision.